WO2021224999A1 - 生理活性物質が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤 - Google Patents
生理活性物質が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤 Download PDFInfo
- Publication number
- WO2021224999A1 WO2021224999A1 PCT/JP2020/018731 JP2020018731W WO2021224999A1 WO 2021224999 A1 WO2021224999 A1 WO 2021224999A1 JP 2020018731 W JP2020018731 W JP 2020018731W WO 2021224999 A1 WO2021224999 A1 WO 2021224999A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- physiologically active
- active substance
- microsphere
- plga
- microspheres
- Prior art date
Links
- 239000004005 microsphere Substances 0.000 title claims abstract description 164
- 239000000126 substance Substances 0.000 title claims abstract description 55
- 230000000975 bioactive effect Effects 0.000 title claims abstract description 45
- 239000003405 delayed action preparation Substances 0.000 title claims description 12
- 239000002245 particle Substances 0.000 claims abstract description 125
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims abstract description 106
- 229920001577 copolymer Polymers 0.000 claims abstract description 12
- 239000013543 active substance Substances 0.000 claims description 154
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 32
- 239000011148 porous material Substances 0.000 claims description 22
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 19
- 239000004310 lactic acid Substances 0.000 claims description 16
- 235000014655 lactic acid Nutrition 0.000 claims description 16
- 239000002904 solvent Substances 0.000 description 58
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 51
- 239000000243 solution Substances 0.000 description 45
- 239000007788 liquid Substances 0.000 description 33
- 239000004372 Polyvinyl alcohol Substances 0.000 description 31
- 229920002451 polyvinyl alcohol Polymers 0.000 description 31
- 239000010419 fine particle Substances 0.000 description 26
- 238000000034 method Methods 0.000 description 26
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 20
- 239000007864 aqueous solution Substances 0.000 description 20
- 238000001878 scanning electron micrograph Methods 0.000 description 19
- 238000003756 stirring Methods 0.000 description 18
- 239000006185 dispersion Substances 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 17
- 239000000725 suspension Substances 0.000 description 16
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 14
- 238000001914 filtration Methods 0.000 description 14
- 239000002270 dispersing agent Substances 0.000 description 12
- 239000012530 fluid Substances 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 238000013268 sustained release Methods 0.000 description 10
- 239000012730 sustained-release form Substances 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000001035 drying Methods 0.000 description 8
- 229910052786 argon Inorganic materials 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 230000002093 peripheral effect Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 229920002988 biodegradable polymer Polymers 0.000 description 6
- 239000004621 biodegradable polymer Substances 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000003589 local anesthetic agent Substances 0.000 description 6
- -1 molecular weight Substances 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000002105 nanoparticle Substances 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 239000010409 thin film Substances 0.000 description 5
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
- 238000002149 energy-dispersive X-ray emission spectroscopy Methods 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical class CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229960004338 leuprorelin Drugs 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 3
- 229960003912 probucol Drugs 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 235000003385 Diospyros ebenum Nutrition 0.000 description 2
- 241000792913 Ebenaceae Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004581 coalescence Methods 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000011258 core-shell material Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010884 ion-beam technique Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 239000002077 nanosphere Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- XOBKSJJDNFUZPF-UHFFFAOYSA-N Methoxyethane Chemical compound CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- DRQXUCVJDCRJDB-UHFFFAOYSA-N Turanose Natural products OC1C(CO)OC(O)(CO)C1OC1C(O)C(O)C(O)C(CO)O1 DRQXUCVJDCRJDB-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 125000001931 aliphatic group Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011362 coarse particle Substances 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 239000002434 gonadorelin derivative Substances 0.000 description 1
- 238000013485 heteroscedasticity test Methods 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002453 idose derivatives Chemical class 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000012643 polycondensation polymerization Methods 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- RULSWEULPANCDV-PIXUTMIVSA-N turanose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](C(=O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RULSWEULPANCDV-PIXUTMIVSA-N 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000008307 w/o/w-emulsion Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/12—Powdering or granulating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2329/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal, or ketal radical; Hydrolysed polymers of esters of unsaturated alcohols with saturated carboxylic acids; Derivatives of such polymer
- C08J2329/02—Homopolymers or copolymers of unsaturated alcohols
- C08J2329/04—Polyvinyl alcohol; Partially hydrolysed homopolymers or copolymers of esters of unsaturated alcohols with saturated carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2367/00—Characterised by the use of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Derivatives of such polymers
- C08J2367/04—Polyesters derived from hydroxy carboxylic acids, e.g. lactones
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2429/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal, or ketal radical; Hydrolysed polymers of esters of unsaturated alcohols with saturated carboxylic acids; Derivatives of such polymer
- C08J2429/02—Homopolymers or copolymers of unsaturated alcohols
- C08J2429/04—Polyvinyl alcohol; Partially hydrolysed homopolymers or copolymers of esters of unsaturated alcohols with saturated carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2467/00—Characterised by the use of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Derivatives of such polymers
- C08J2467/04—Polyesters derived from hydroxy carboxylic acids, e.g. lactones
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/04—Oxygen-containing compounds
- C08K5/07—Aldehydes; Ketones
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/04—Oxygen-containing compounds
- C08K5/13—Phenols; Phenolates
- C08K5/132—Phenols containing keto groups, e.g. benzophenones
Definitions
- the present invention relates to a microsphere in which a physiologically active substance is uniformly dispersed and a sustained release preparation containing the same.
- the present invention particularly relates to a microsphere containing a lactic acid / glycolic acid copolymer (PLGA) in which a physiologically active substance is uniformly dispersed as a main component, and a sustained release preparation containing the same.
- PLGA lactic acid / glycolic acid copolymer
- microspheres or nanospheres have been attracting attention as sustained release preparations such as pharmaceuticals containing physiologically active substances.
- the microsphere usually refers to a preparation having a particle size of about 1 ⁇ m to 150 ⁇ m, and a smaller preparation having a particle size of less than 1 ⁇ m is called a nanosphere.
- the bioactive substance can be encapsulated in a biodegradable synthetic polymer or a natural polymer to continuously release the bioactive substance locally, or the targeting of the bioactive substance to a tissue, etc. It can be performed.
- a sustained release microsphere preparation that gradually releases a physiologically active substance at a constant rate
- a preparation in which biodegradable polymers, physiologically active substances, additives, solvents, etc. are appropriately controlled is required. ..
- the initial release amount of the physiologically active substance and the release rate during the subsequent release period should be appropriately controlled for physiology. It is necessary to continuously release the active substance in vivo for a certain period of time.
- lactic acid / glycolic acid copolymer Polylactide-co-glycolic acid Acid, PLGA
- PLGA Polylactide-co-glycolic acid Acid
- the particle size of the microsphere and the physiological activity in the microsphere are to be controlled.
- the state of dispersion of the substance is relevant.
- the particle size of the microsphere has a problem of yield, it can be adjusted to the target particle size by an operation such as filtration.
- the dispersed state of the physiologically active substances in the microspheres is only uniform and has not been confirmed.
- PLGA microspheres can be produced by, for example, a submerged drying method, a spray drying method, a spray freeze drying method, a drying method using a supercritical fluid step, a double emulsification method, or the like.
- the most common production method among these is to dissolve or disperse PLGA and the physiologically active substance in an organic solvent when the physiologically active substance is lipophilic, and mix it with an aqueous solution in which polyvinyl alcohol (PVA) is dissolved to form an emulsion.
- PVA polyvinyl alcohol
- Patent Document 1 describes a method for producing a sustained-release microsphere containing a biodegradable polymer such as PLGA and a peptide drug by a spray drying method, a spray freeze drying method, or a drying method using a supercritical fluid step. It is disclosed. However, it is not described how much the particle size of the sustained release microspheres varies, whether the peptide drug is uniformly dispersed in the sustained release microspheres, or whether a uniform one can be obtained. ..
- Patent Document 2 PLGA fine particles are dried by an in-liquid method using a mixed solvent consisting of a halide hydrocarbon and a non-miscible organic solvent having a drug solubility of 0.3% (W / V) or more.
- the method of manufacture is disclosed. It is described that the particle size (median diameter) of the fine particles obtained in Production Examples 1 and 2 was 14 and 16 ⁇ m, but the dispersed state of the drug in the fine particles is not described.
- Patent Document 3 discloses PLGA nanoparticles containing a bioactive substance. These nanoparticles are mainly for targeting to a specific tissue, and are nanoparticles having a size of several tens to several hundreds of nm that can pass through minute holes in capillaries. However, Patent Document 3 does not describe microspheres of 1 ⁇ m or larger, which are much larger than these nanoparticles. Further, even by using the technique of Patent Document 3, those skilled in the art could not produce microspheres having a particle size of 1 ⁇ m or more.
- Patent Document 4 discloses a preparation that releases leuprorelin acetate, which is a luteinizing hormone-releasing hormone derivative, by subcutaneous injection over a period of about one to several months.
- the formulation has a problem that the particle size distribution of the particle size is very wide, from 1 ⁇ m to 400 ⁇ m. Therefore, Patent Document 5 proposes a method for producing a microsphere in which a physiologically active substance is encapsulated in a polymer for a carrier by a double emulsification method as a method for solving this problem.
- the leuprorain acetate-containing microspheres obtained in Examples 1 to 5 do not describe the dispersed state of the drug in the particles.
- Patent Document 6 discloses a microsphere that reduces chronic pain for at least 28 days (672 hours).
- the microsphere contains a biodegradable polymer and a local anesthetic (physiologically active substance), about 75% of the local anesthetic is released by about 72 hours, and about 80-90% of the local anesthetic is about 80-90%. Released by 120 hours. This suggests that the distribution of local anesthetics in the microspheres is not uniform but biased outwards in the microspheres. From the SEM (scanning electron microscope) image of the cross section of the microsphere shown in FIG. 2, the dispersed state of the local anesthetic cannot be determined, and the local anesthetic or vacancies of 1.5 ⁇ m or more are confirmed.
- SEM scanning electron microscope
- Patent Document 7 discloses a microsphere having a core-shell structure in which the core contains aripiprazole in a solid state and a shell containing a biodegradable polymer covers the surface of the core.
- the microspheres of Patent Document 7 are not those in which the physiologically active substance is uniformly dispersed in the microspheres. Further, according to the electron micrograph of the cross section of the microsphere obtained in the example shown in FIG. 5, pores larger than 1.5 ⁇ m are confirmed.
- Japanese Unexamined Patent Publication No. 2005-035994 Japanese Unexamined Patent Publication No. 2005-015476 Japanese Patent No. 4856752 Japanese Patent No. 2653255 Japanese Unexamined Patent Publication No. 2014-224114 Japanese Unexamined Patent Publication No. 2016-069378 Special Table 2010-531303
- the release period is realized as designed unless the distribution of physiologically active substances and pores in the microspheres are controlled. Can not do it.
- the bioactive substance is biased near the surface of the microsphere, a large amount of the bioactive substance is released from the microsphere in the early stage after administration, which causes a problem of initial burst.
- the bioactive substance is biased toward the center of the microsphere, or if it is in a state like a core shell, it cannot be continuously released from the initial stage.
- it is desirable that the fine particles of the physiologically active substance are uniformly dispersed. In a dispersed state in which large lumps of bioactive substances are scattered, it cannot be continuously released from the initial stage.
- similar problems will occur in the release of bioactive substances.
- bioactive substance It is an absolute condition for the bioactive substance to be continuously released in the living body for a certain period of time that the bioactive substance is uniformly dispersed in the microsphere. Since the particle size of microspheres is large unlike nanoparticles, it is generally difficult to make them uniform. Therefore, it is necessary to confirm the dispersed state of the physiologically active substance in the microsphere.
- FIG. 1 shows 1.88 mg (manufactured by Takeda Pharmaceutical Company Limited) for injection of the microcapsule modified sustained release agent Leuprin®, which corresponds to the long-term sustained release microcapsules of the LH-RH derivative described in Patent Document 4. ) Is a micrograph.
- This preparation contains various particles from large particles to small particles. A typical particle of about 35 ⁇ m is selected, and an SEM (scanning electron microscope) image of the cross section of the particle is shown in FIG. be. Comparing with FIG. 3, which is an SEM image of PLGA fine particles containing no physiologically active substance in Reference Example 1, dispersed physiologically active substances and pores are confirmed in FIG. Many vacancies are confirmed.
- Elemental analysis with EDS (Energy Dispersive X-ray Spectroscopy) confirms either bioactive substances or vacancies. In such a dispersed state in which the physiologically active substances dispersed in the particles are not uniform, the release rate during the release period cannot be appropriately controlled.
- the subject of the present invention is that the initial release amount of the physiologically active substance and the release rate during the subsequent release period are appropriately controlled, and the physiologically active substance can be continuously released in the living body for a certain period of time. To provide fairs.
- the present invention has been completed by finding that the initial release amount of the active substance and the release rate during the subsequent release period are appropriately controlled, and the physiologically active substance can be continuously released in the living body for a certain period of time. That is, the present invention is as follows.
- the first aspect of the present invention is a microsphere containing a lactic acid / glycolic acid copolymer (PLGA) in which a physiologically active substance is uniformly dispersed as a main component, and the average volume of the microsphere.
- the microsphere has a reference particle size of 1 ⁇ m or more and 150 ⁇ m or less, and has no lumps or pores of the physiologically active substance of 1.5 ⁇ m or more in the microsphere.
- the second aspect of the present invention is the microsphere according to [1], wherein the microsphere has no mass or pore of 1.0 ⁇ m or more of the physiologically active substance.
- the third aspect of the present invention is the microsphere according to [1] or [2], wherein the dispersed average volume reference particle size of the physiologically active substance is 5 nm to 500 nm.
- the fourth aspect of the present invention is the microsphere according to any one of [1] to [3], wherein the bioactive substance is a lipophilic bioactive substance.
- a fifth aspect of the present invention is a sustained release preparation containing the microspheres according to any one of [1] to [4].
- the initial release amount of the physiologically active substance and the release rate during the subsequent release period are appropriately controlled, and the physiologically active substance can be continuously released in the living body for a certain period of time.
- 6 is an SEM image of a cross section of a particle of about 35 ⁇ m of Leuprorelin®. 6 is an SEM image of a cross section of a microsphere containing no physiologically active substance of Reference Example 1. 6 is an SEM image of a cross section of the microsphere of Example 1. It is an SEM image of the cross section of the microsphere of Comparative Example 2. 6 is an SEM image of a cross section of the microsphere of Comparative Example 3.
- the microsphere of the present invention is a microsphere containing a lactic acid / glycolic acid copolymer (PLGA) in which a physiologically active substance is uniformly dispersed as a main component, and is based on the average volume of the microsphere. It is a microsphere having a particle size of 1 ⁇ m or more and 150 ⁇ m or less, and having no mass or pores of the physiologically active substance of 1.5 ⁇ m or more in the microsphere. According to the microsphere of the present invention, the initial release amount of the physiologically active substance and the release rate during the subsequent release period are appropriately controlled, and the physiologically active substance can be continuously released in the living body for a certain period of time.
- PLGA lactic acid / glycolic acid copolymer
- the lumps mean coarse particles or aggregates of the physiologically active substance
- the vacancy means bubbles or grooves.
- 1.5 ⁇ m or more means a cavity having a maximum diameter of 1.5 ⁇ m or more when the size is substantially circular, a long side when the size is rectangular, and a maximum length of 1.5 ⁇ m or more when the size is needle-shaped.
- the absence of lumps or vacancies of the bioactive substance of 1.5 ⁇ m or more or 1.0 ⁇ m or more in the microsphere means that, for example, the cross section of the microsphere can be seen at a magnification that allows the dispersed fine particles of the bioactive substance to be confirmed. It can be confirmed by observing with an electron micrograph. Specifically, first, the microspheres are frozen in liquid nitrogen. After freezing, a FIB (Focused Ion Beam) cross section is prepared. That is, the cross section of the microsphere is observed by irradiating the sample with a focused ion beam using a FIB device and cutting out the structure at a desired position inside the sample.
- FIB Fluorused Ion Beam
- the preferred particle size of the dispersed fine particles of the physiologically active substance is several tens of nm to several hundreds of nm, and the entire cross section of the microsphere is observed at an observation magnification of an electron microscope capable of confirming the dispersed fine particles of this size.
- the observation magnification of an electron microscope is about 2500 to tens of thousands of times or more.
- the observed parts may be joined to observe the entire microsphere.
- the cross section of the microsphere can be elementally analyzed by EDS (Energy Dispersive X-ray Spectroscopy).
- PLGA is a lactic acid / glycolic acid copolymer having a structural unit derived from lactic acid and a structural unit derived from glycolic acid.
- PLGA may contain other biodegradable macromolecules such as polylactide (PLA), polyglycolide (PGA).
- PLA polylactide
- PGA polyglycolide
- the molar ratio (L: G) of the structural unit (L) derived from lactic acid and the structural unit (G) derived from glycolic acid in PLGA is not particularly limited and may be appropriately selected depending on the purpose. However, it is preferably 1:99 to 99: 1, more preferably 25:75 to 99: 1, further preferably 30:70 to 90:10, and particularly preferably 50:50 to 85:15.
- the PLGA used in the microspheres of the present invention can be produced, for example, by heating lactic acid and glycolic acid under a weak reduced pressure using an ion exchange resin as a catalyst and performing condensation polymerization. At that time, lactide may be used instead of lactic acid.
- PLGA may be a commercially available product. As a commercially available product, for example, it can be purchased from Fujifilm Wako Pure Chemical Industries, Ltd., Taki Chemical Co., Ltd., Evonik Rohm GmbH, Merck, Sigma-Aldrich, and the like.
- the content of PLGA in the microsphere of the present invention is not particularly limited and may be appropriately selected depending on the intended purpose, but is preferably 1% by mass or more, and even more preferably 30% by mass or more and 95% by mass or less. 50% by mass or more and 90% by mass or less is particularly preferable.
- the microspheres of the present invention include PLGA and bioactive substances. Further, if necessary, it contains a dispersant and other components. Physiologically active substances, dispersants, other components and the like are dispersed in the matrix of microspheres.
- the physiologically active substance contained in the microspheres of the present invention is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include pharmaceutical compounds, functional food compounds and functional cosmetic compounds.
- the microsphere containing the pharmaceutical compound can be suitably used as, for example, a sustained release pharmaceutical preparation.
- the bioactive substance includes both a lipophilic bioactive substance and a hydrophilic bioactive substance.
- a lipophilic bioactive substance is mentioned as a preferable bioactive substance.
- the lipophilic physiologically active substance means, for example, a substance having a logP value of 3 or more in the water / octanol partition coefficient, and a physiologically active substance not included in the lipophilic physiologically active substance is classified as a hydrophilic physiologically active substance.
- the water / octanol partition coefficient can be measured according to the JISZ7260-107 (2000) flask shaking method.
- the physiologically active substance is not particularly limited as long as a sustained release preparation is desired, and can be appropriately selected depending on the intended purpose.
- the physiologically active substance includes any form such as a salt and a hydrate.
- the preferable content of the physiologically active substance varies depending on the physiologically active substance, but is, for example, 0.01 to 2% by mass, preferably 0.1 to 1.5% by mass, based on the total amount of microspheres. %, More preferably 0.2 to 1.2% by mass.
- the average volume reference particle size of the dispersed fine particles of the physiologically active substance is preferably 5 nm to 500 nm, more preferably 10 nm to 400 nm, and further preferably 20 nm to 200 nm.
- Dispersants can be used to disperse the bioactive substance.
- the dispersant may be a low molecular weight dispersant or a high molecular weight dispersant polymer.
- a low molecular weight dispersant means a compound having a weight average molecular weight of less than 15,000, and a high molecular weight dispersant polymer contains repeated covalent bonds between one or more monomers and has a weight average molecular weight of less than 15,000. Means more than 15,000 compounds.
- the low molecular weight dispersant is not particularly limited as long as it is acceptable for pharmaceutical compounds, functional food compounds, functional cosmetic compounds, etc., and can be appropriately selected according to the purpose. Specific examples thereof include lipids, sugars, cyclodextrins, amino acids, organic acids, and other components. These may be used alone or in combination of two or more.
- the lipids are not particularly limited and may be appropriately selected depending on the intended purpose.
- medium-chain or long-chain monoglycerides may be appropriately selected depending on the intended purpose.
- medium-chain or long-chain monoglycerides may be appropriately selected depending on the intended purpose.
- diglycerides or triglycerides may be appropriately selected depending on the intended purpose.
- phospholipids eg, soybean oil, avocado oil, squalane oil).
- vegetable oils eg, soybean oil, avocado oil, squalane oil.
- Sesame oil olive oil, corn oil, rapeseed oil, saflower oil, sunflower oil, etc.
- fish oil seasoning oil
- water-insoluble vitamins fatty acids, and mixtures thereof, and derivatives thereof.
- the saccharide is not particularly limited and may be appropriately selected depending on the intended purpose.
- glucose, mannose, idose, galactose, fucose, ribose, xylose, lactose, sucrose, maltoce, trehalose, turanose, raffinose and maltotriose examples thereof include ose, acarbose, water-soluble cellulose, synthetic cellulose, sugar alcohol, glycerin, sorbitol, lactitol, maltotriose, mannitol, xylose, erythritol, or polyol, or derivatives thereof. These may be used alone or in combination of two or more.
- the other ingredients are not particularly limited and can be appropriately selected according to the purpose, but those that can be conventionally used in medicine are preferable.
- the average volume reference particle size of the microspheres of the present invention is 1 ⁇ m or more and 150 ⁇ m or less, preferably 10 ⁇ m or more and 100 ⁇ m or less, and more preferably 20 ⁇ m or more and 75 ⁇ m or less.
- the average volume reference particle size can be measured using a laser diffraction type particle size distribution measuring device.
- the average volume reference particle size exceeds 150 ⁇ m, the problem of initial burst occurs due to the heteroscedasticity of the physiologically active substance in the microsphere, and the problem of initial burst occurs, and aggregation and sedimentation are likely to occur. Will also be difficult. If it is smaller than 1 ⁇ m, the problem of initial burst occurs remarkably.
- the initial release amount of the physiologically active substance and the release rate during the subsequent release period are appropriately controlled, and the physiologically active substance can be continuously released in the living body for a certain period of time.
- sustained release preparation Using the microspheres of the present invention, a sustained release preparation containing microspheres can be prepared.
- the sustained release preparation of the present invention appropriately controls the initial release amount of the physiologically active substance and the release rate during the subsequent release period, and continuously releases the physiologically active substance for a certain period of time in the living body, effectively as a drug. Can show a physical effect.
- the sustained release preparation of the present invention can be easily administered as an injection and an implant, or as a transdermal agent, directly into lesions such as intramuscular, subcutaneous, blood vessels, organs, joint cavities, and tumors. It can also be administered as various other pharmaceutical forms.
- a dispersant Teween 80, HCO-60, carboxymethyl cellulose, sodium alginate, etc.
- a preservative methylparaben, propylparaben, etc.
- an isotonic agent chloride
- the method for producing a microsphere of the present invention includes at least a particle forming step, and may further include a filtration sterilization step, a good solvent removing step, and other steps, if necessary.
- the particle forming step is a plurality of processes described in JP-A-2009-132871 or JP-A-2011-189348, which are arranged so as to be close to each other and which can be separated from each other, and at least one of them rotates relative to the other. It is preferable to use a particle processing apparatus in which particle processing is performed between the surfaces.
- the particle forming step includes, for example, a solution of PLGA and a physiologically active substance obtained by dissolving or dispersing PLGA and a physiologically active substance in a good solvent of PLGA using the above-mentioned particle processing apparatus, and a poor solvent of PLGA.
- microspheres of the present invention It is carried out by precipitating the microspheres of the present invention by continuously adding a solution to prepare emulsified particles and removing a good solvent from the prepared particles.
- “dispersion” means that a physiologically active substance is dispersed in a good PLGA solvent as a solid, that a physiologically active substance is emulsified in a good PLGA solvent, and that an aqueous solution of a hydrophilic physiologically active substance and a good PLGA are used. It includes forming a w / o emulsion containing a solvent and the like.
- the solution of PLGA and the physiologically active substance is not particularly limited as long as it is a solution in which PLGA and the physiologically active substance are dissolved or dispersed in a good solvent of PLGA, and can be appropriately selected depending on the intended purpose.
- the good solvent is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include halogenated aliphatic hydrocarbons, aliphatic esters, alcohols, ketones, ethers and acetonitrile. Examples of the halogenated aliphatic hydrocarbon include dichloromethane, chloroform, carbon tetrachloride, chloroethane, 2,2,2-trichloroethane and the like.
- Examples of the aliphatic ester include ethyl acetate, propyl acetate, butyl acetate and the like.
- Examples of the alcohol include alcohols having low solubility in water such as benzyl alcohol, phenyl alcohol, and n-butanol.
- Examples of the ketone include ketones having 3 to 6 carbon atoms (for example, acetone, methyl ethyl ketone, methyl isobutyl ketone, cyclohexanone, etc.).
- Examples of the ether include ethers having 2 to 6 carbon atoms (for example, dimethyl ether, methyl ethyl ether, diethyl ether, etc.).
- a solvent having a low solubility in water from the viewpoint of the content of the physiologically active substance and the purpose of preventing the initial burst.
- Preferred good solvents include halogenated aliphatic hydrocarbons, ketones, and mixed solvents thereof, and more preferably dichloromethane, acetone, and mixed solvents thereof. Further, these may be used individually by 1 type, or may be used in combination of 2 or more type.
- the particle size can be controlled by changing the solvent type and the mixing amount.
- a good solvent means a solvent having a high solubility of PLGA
- a poor solvent means a solvent having a low solubility of PLGA or an insoluble solvent.
- the good solvent and the poor solvent are selected so that the cross section of the microsphere does not have lumps or vacancies of a physiologically active substance of 1.5 ⁇ m or more.
- the good solvent and the poor solvent can be defined by, for example, the mass of PLGA that can be dissolved in 100 g of the solvent at 25 ° C.
- the good solvent is preferably a solvent that dissolves 0.1 g or more of PLGA, more preferably 0.2 g or more, and further preferably 0.5 g or more.
- the poor solvent is preferably a solvent that dissolves only 0.05 g or less of PLGA, more preferably 0.02 g or less, and further preferably 0.01 g or less.
- the poor solvent is not particularly limited and may be appropriately selected depending on the intended purpose, but water is preferable.
- the content of PLGA in the solution of PLGA and the bioactive substance depends on the good solvent, the particle size of the target microsphere, and the cross section of the microsphere is 1.5 ⁇ m or more of the bioactive substance. It can be varied so that there are no lumps or vacancies.
- the content of PLGA is, for example, 1 to 30% by mass, preferably 3 to 20% by mass, and more preferably 5 to 15% by mass.
- the content of the bioactive substance in the PLGA solution should be appropriately changed according to the purpose, pharmacological effect, etc., and so that there are no lumps or vacancies of the bioactive substance of 1.5 ⁇ m or more in the cross section of the microsphere. Can be done.
- a stabilizer may be added to the antisolvent.
- the stabilizer is not particularly limited and may be appropriately selected depending on the intended purpose.
- polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), carboxymethylcellulose (CMC), hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose (HPMC), lecithin, polysorbate 80 and the like can be mentioned, with polyvinyl alcohol (PVA) being preferred. ..
- the concentration of the stabilizer to be added is preferably 0.01 to 20% by mass, and more preferably 5% by mass or less.
- Preferred poor solvents include, for example, an aqueous PVA solution.
- the solution containing PLGA and physiologically active substances and the solution containing a poor solvent are those in which a stirrer of various shapes such as rod-shaped, plate-shaped, and propeller-shaped is rotated in a tank, and a screen that rotates relative to the stirrer. It is desirable that the fluid is prepared by using a preparation device such as a rotary disperser that realizes uniform mixing by applying a shearing force to the fluid. As a preferred example of the rotary disperser, the stirrer disclosed in Japanese Patent No. 5147091 can be applied. It is necessary to completely mix the PLGA solution and the product solvent so that the cross section of the microsphere does not have lumps or pores of a physiologically active substance of 1.5 ⁇ m or more. For complete mixing, it is necessary to aim for homogenization at least at the molecular level.
- the rotary disperser may be a batch type or a continuous type.
- the fluid may be continuously supplied to and discharged from the stirring tank, or may be performed using a continuous mixer without using the stirring tank.
- the stirring energy can be appropriately controlled by using a known stirring machine or stirring means.
- the stirring energy is described in detail in Japanese Patent Application Laid-Open No. 04-114725 by the present applicant.
- the stirring method in the present invention is not particularly limited, but it can be carried out by using various shearing type, friction type, high pressure jet type, ultrasonic type and other stirring machines, melting machines, emulsifying machines, dispersers, hojinizers and the like. ..
- Ultra Talux manufactured by IKA
- Polytron manufactured by Kinematica
- TK Homo Mixer manufactured by Primix
- Ebara Milder manufactured by Ebara Corporation
- TK Homomic Line Flow manufactured by Primix
- Colloid Mill Shainko Environment
- Continuous emulsifiers such as Solution
- slasher manufactured by Nippon Coke Industries
- trigonal wet pulverizer manufactured by Mitsui Miike Kakoki
- Cavitron manufactured by Eurotech
- fine flow mill manufactured by Pacific Kiko
- Claremix M
- -Batch type or continuous dual-purpose emulsifiers such as (manufactured by Technique) and Claremix Dissolver (manufactured by M-Technique) can be mentioned.
- the stirring process is provided with a stirring blade that rotates at high speed, a screen is provided on the outside of the stirring blade, and a stirrer that discharges fluid as a jet flow from the opening of the screen, particularly the above-mentioned Cumix (the above-mentioned Mariemix). It is desirable to use M-Technique) or Clairemix Dissolver (M-Technique).
- the particle size and particle size distribution of PLGA fine particles can be controlled by adjusting the contact pressure when the rotating processing surface is stopped.
- the contact pressure is preferably 20 g / cm 2 to 250 g / cm 2 .
- the contact pressure is lower than 20 g / cm 2 , the thin film is not stable and the particle size distribution becomes wide. It was found that if the contact pressure is higher than 250 g / cm 2, it becomes difficult to adjust the target particle size. More preferably, 50 g / cm 2 to 200 g / cm 2 is mentioned, and more preferably 80 g / cm 2 to 150 g / cm 2 is mentioned.
- each of the microspheres formed by the contact between the solution of PLGA and the physiologically active substance and the solution containing the poor solvent is preferable to prevent each of the microspheres formed by the contact between the solution of PLGA and the physiologically active substance and the solution containing the poor solvent from coalescing.
- a method for preventing the coalescence it is preferable to put a solution containing a poor solvent in advance in the solution discharge liquid recovery tank and stir gently. By performing stirring, coalescence of microspheres can be further suppressed.
- a rotary disperser is preferable, and a Clairemix dissolver (manufactured by M-Technique) is preferable. It is not particularly limited as long as it can flow the whole gently. If the stirring is strong, the PLGA emulsified particles may be broken, the distribution width may be widened, and the dispersed state of the physiologically active substance may be disrupted.
- the particle forming step can be suitably carried out according to the above description, and microspheres can be produced.
- the physiologically active substance is a hydrophilic physiologically active substance
- the hydrophilic physiologically active substance is dispersed in a good solvent of PLGA by using, for example, a dispersant, so that the particle formation step is similarly carried out to obtain a microsphere. Can be manufactured.
- the physiologically active substance is a hydrophilic physiologically active substance
- a solution in which the hydrophilic physiologically active substance is dissolved in an aqueous solvent such as water together with a stabilizer as necessary, and PLGA is dissolved in a good solvent of PLGA can also be used as a solution of PLGA and a physiologically active substance, and the above-mentioned particle formation step can be carried out by using the above-mentioned particle formation treatment apparatus.
- an intermittent shaking method for the preparation of the w / o emulsion, an intermittent shaking method, a propeller type stirrer, a method using a mixer using a turbine type stirrer, a colloid mill method, a homogenizer method, and an ultrasonic irradiation method can be used.
- the solution of PLGA and the physiologically active substance which is the w / o emulsion and the solution containing the poor solvent of PLGA are continuously added to prepare the emulsified particles as the w / o / w emulsion. It is carried out by precipitating the microspheres of the present invention by preparing and removing a good solvent from the prepared particles.
- This microsphere can be used as it is, but it can also be solidified by adding excipients (mannitol, sorbitol, lactose, glucose, etc.), redispersing, and then freeze-drying or spray-drying.
- This solidified microsphere can be used to obtain a more stable sustained release injection by adding distilled water for injection or an appropriate dispersion medium at the time of use.
- the above-mentioned filtration sterilization filter is not particularly limited and can be appropriately selected according to the purpose.
- hydrophilic filters such as polyvinylidene fluoride (PVDF) and polyether sulfone can be mentioned.
- PVDF polyvinylidene fluoride
- PTFE polytetrafluoroethylene
- the material is not limited to the materials described here, and it is necessary to select the material according to the adsorption of the drug and the solvent type.
- the good solvent is removed from the emulsified particles containing PLGA and a physiologically active substance.
- the good solvent can be removed from the liquid containing the emulsified particles without forming lumps or pores of a physiologically active substance of 1.5 ⁇ m or more in the cross section of the microsphere.
- the good solvent is evaporated from the liquid by at least one of heating the liquid with stirring, flowing a gas such as nitrogen on the liquid surface of the liquid, and depressurizing the liquid. Examples include a method of removing.
- the good solvent it is preferable to remove the good solvent as soon as possible in order to prevent the formation of lumps or pores of the physiologically active substance having a size of 1.5 ⁇ m or more or 1.0 ⁇ m or more in the microsphere.
- Examples of the time for removing the good solvent include 30 minutes to 12 hours, preferably 1 to 10 hours, and more preferably 2 to 8 hours.
- Reference Example 1 In Reference Example 1, microspheres (PLGA fine particles) containing no physiologically active substance were prepared. By observing the cross sections of the microspheres of Examples and Comparative Examples with SEM images using the microspheres of Reference Example 1 as an index, the dispersed state of the physiologically active substances in the microspheres of Examples and Comparative Examples was confirmed below.
- Ion-exchanged water was added so that polyvinyl alcohol (PVA, EG-40P, manufactured by Nippon Synthetic Chemical Industry Co., Ltd.) was 1.5% by mass, and dissolved using a high-speed rotary disperser Clairemix (manufactured by M-Technique). An aqueous PVA solution was obtained. Then, filtration was performed with a hydrophilic PVDF membrane filter ( ⁇ 47, manufactured by Merck). A PVA aqueous solution was placed in advance in a tank for collecting PLGA emulsified particles, and the mixture was stirred to the extent that the liquid level moved.
- PVA polyvinyl alcohol
- EG-40P manufactured by Nippon Synthetic Chemical Industry Co., Ltd.
- the prepared PLGA solution and PVA aqueous solution were mixed using the particle processing apparatus described in JP-A-2011-189348.
- the particle processing apparatus described in JP-A-2011-189348 is the apparatus described in FIG. 25 of the same publication, in which the second introduction port d20 is a ring-shaped disk at the center of the processing surface 2. It has a concentric ring shape surrounding the opening, and has a disk diameter of 75 mm.
- the prepared PVA aqueous solution was introduced between the first introduction section d1 and the treatment surfaces 1 and 2 at 0.02 MPaG, 65 mL / min, 30 ° C., and the treatment section 10 was rotated at 2000 rpm.
- the prepared PLGA solution was introduced from the second introduction section d2 between the treatment surfaces 1 and 2 at 0.65 MPaG, 20 mL / min, 30 ° C., and the PVA aqueous solution and the PLGA solution were mixed in a forced thin film.
- PLGA emulsified particles containing dichloromethane were prepared between the treatment surfaces 1 and 2.
- a fluid containing PLGA emulsified particles between the treatment surfaces 1 and 2 (hereinafter referred to as PLGA emulsified particle dispersion) was discharged from the treatment surfaces 1 and 2 of the particle processing apparatus.
- the PLGA emulsified particle dispersion was collected in a recovery tank via an outer casing 61 for collecting the discharged PLGA emulsified particle dispersion.
- the discharged liquid was stirred using a clear mix dissolver (manufactured by M-Technique) at a peripheral speed of 4.7 m / sec, and argon gas was blown onto the liquid surface for 3.5 hours. Then, dichloromethane was removed to obtain a suspension containing PLGA fine particles (PLGA fine particle suspension).
- the average volume-based particle diameter of the obtained PLGA fine particles was 34.0 ⁇ m, and typical particles were frozen in liquid nitrogen, a FIB cross section was prepared, and an SEM image (FIG. 3) was observed.
- Example 1 ⁇ Preparation of PLGA and bioactive substance solutions and PVA aqueous solution> Lactic acid / glycolic acid copolymer (Resomer RG504, manufactured by Ebonic) is 13% by mass, and progesterone (manufactured by Fujifilm Wako Pure Chemicals, for cell biochemistry) is 1.0% by mass as a physiologically active substance. Kanto Chemical Co., Ltd.) was added and dissolved using a high-speed rotary disperser Clairemix Dissolver (manufactured by M-Technique) to obtain a solution of PLGA and a physiologically active substance. Then, filtration was performed with a 0.2 ⁇ m air vent filter ( ⁇ 62, manufactured by Merck & Co., Ltd.).
- the PVA aqueous solution was prepared in the same manner as in Reference Example 1. An aqueous PVA solution was placed in advance in a tank for collecting emulsified particles of PLGA and a physiologically active substance, and the mixture was stirred to the extent that the liquid level moved.
- the prepared solution of PLGA and the physiologically active substance and the aqueous solution of PVA were mixed in the same manner as in Reference Example 1 using the particle processing apparatus described in JP-A-2011-189348. Specifically, the prepared PVA aqueous solution was introduced between the first introduction section d1 and the treatment surfaces 1 and 2 at 0.02 MPaG, 65 mL / min, 30 ° C., and the treatment section 10 was rotated at 2000 rpm.
- the prepared solution of PLGA and the physiologically active substance was introduced from the second introduction part d2 between the treatment surfaces 1 and 2 at 0.65 MPaG, 20 mL / min, 30 ° C., and the PVA aqueous solution and the PLGA and the physiologically active substance were introduced.
- a fluid containing the emulsified particles of PLGA and the physiologically active substance (hereinafter referred to as the emulsified particle dispersion of PLGA and the physiologically active substance) between the treatment surfaces 1 and 2 was discharged from the processing surfaces 1 and 2 of the particle processing apparatus.
- the PLGA and the emulsified particle dispersion of the physiologically active substance were collected in a recovery tank via the outer casing 61 for collecting the discharged PLGA and the emulsified particle dispersion of the physiologically active substance.
- the discharged liquid was stirred with a Clairemix dissolver (manufactured by M-Technique) at a peripheral speed of 4.7 m / sec, and argon gas was blown onto the liquid surface for 3.5 hours.
- Dichloromethane was removed by sprinkling to obtain a suspension containing microspheres (microsphere suspension).
- the average volume reference particle diameter of the obtained microspheres was 35.5 ⁇ m, and typical particles were frozen in liquid nitrogen, a FIB cross section was prepared, and an SEM image (FIG. 4) was observed.
- the physiologically active substance As shown in FIG. 4, there are no lumps or pores of the physiologically active substance of 1.5 ⁇ m or more in the above-mentioned FIB cross section, and the physiologically active substance is uniformly dispersed as fine particles of 0.1 ⁇ m to 0.22 ⁇ m in the microsphere. It was confirmed that there was.
- Example 2 In the same manner as in Example 1, PLGA and an emulsified particle dispersion of a physiologically active substance were prepared as a particle forming step. Next, as a solvent removal step, the recovered discharge liquid was stirred using a Clairemix dissolver (manufactured by M-Technique) at a peripheral speed of 4.7 m / sec, and argon gas was flown to remove dichloromethane over 8 hours. Then, a suspension containing microspheres (microsphere suspension) was obtained. The average volume reference particle diameter of the obtained microspheres was 35.3 ⁇ m, and typical particles were frozen in liquid nitrogen, a FIB cross section was prepared, and an SEM image was observed.
- a Clairemix dissolver manufactured by M-Technique
- Example 1 In the same manner as in Example 1, PLGA and an emulsified particle dispersion of a physiologically active substance were prepared as a particle forming step. Next, as a solvent removal step, dichloromethane was removed in the air for 15 hours while stirring the recovered discharge liquid using a Clairemix dissolver (manufactured by M-Technique) at a peripheral speed of 4.7 m / sec, and micron. A suspension containing spheres (microsphere suspension) was obtained. The average volume reference particle diameter of the obtained microspheres was 35.4 ⁇ m, and typical particles were frozen in liquid nitrogen, a FIB cross section was prepared, and an SEM image was observed.
- a solvent removal step dichloromethane was removed in the air for 15 hours while stirring the recovered discharge liquid using a Clairemix dissolver (manufactured by M-Technique) at a peripheral speed of 4.7 m / sec, and micron. A suspension containing spheres (microsphere suspension) was obtained. The average volume reference particle diameter of the obtained
- Example 3 Dichloromethane (Kanto) so that lactic acid / glycolic acid copolymer (Resomer RG504, manufactured by Ebony) is 13% by mass, and Probucol (manufactured by Fujifilm Wako Pure Chemicals, biochemical) is 0.75% by mass as a physiologically active substance. (Chemical) was added and dissolved using a high-speed rotary disperser Clairemix Dissolver (manufactured by M-Technique) to obtain a solution of PLGA and a physiologically active substance. Then, filtration was performed with a 0.2 ⁇ m air vent filter ( ⁇ 62, manufactured by Merck & Co., Ltd.).
- the PVA aqueous solution was prepared in the same manner as in Reference Example 1. An aqueous PVA solution was placed in advance in a tank for collecting emulsified particles of PLGA and a physiologically active substance, and the mixture was stirred to the extent that the liquid level moved.
- the prepared solution of PLGA and the physiologically active substance and the aqueous solution of PVA were mixed in the same manner as in Reference Example 1 using the particle processing apparatus described in JP-A-2011-189348. Specifically, the prepared PVA aqueous solution was introduced between the first introduction section d1 and the treatment surfaces 1 and 2 at 0.025 MPaG, 50 mL / min, 30 ° C., and the treatment section 10 was rotated at 1800 rpm.
- the prepared solution of PLGA and the physiologically active substance was introduced from the second introduction part d2 between the treatment surfaces 1 and 2 at 0.6 MPaG, 16 mL / min, 30 ° C., and the PVA aqueous solution and the PLGA and the physiologically active substance were introduced.
- a fluid containing the emulsified particles of PLGA and the physiologically active substance (hereinafter referred to as the emulsified particle dispersion of PLGA and the physiologically active substance) between the treatment surfaces 1 and 2 was discharged from the processing surfaces 1 and 2 of the particle processing apparatus. ..
- the PLGA and the emulsified particle dispersion of the physiologically active substance were collected in the recovery tank via the outer casing 61 for collecting the discharged PLGA and the emulsified particle dispersion of the physiologically active
- the discharged liquid was agitated at a peripheral speed of 4.7 m / sec using a Clairemix dissolver (manufactured by M-Technique), and argon gas was blown onto the liquid surface to flow 2.0.
- Dichloromethane was removed over time to obtain a suspension containing microspheres (microsphere suspension).
- the average volume reference particle diameter of the obtained microspheres was 28.5 ⁇ m, and typical particles were frozen in liquid nitrogen, a FIB cross section was prepared, and an SEM image was observed.
- Example 4 Dichloromethane (Kanto) so that lactic acid / glycolic acid copolymer (Resomer RG504, manufactured by Ebonic) is 13% by mass, and Probucol (Fujifilm Wako Pure Chemical Co., Ltd., for biochemistry) is 1.0% by mass as a physiologically active substance. (Chemical) was added and dissolved using a high-speed rotary disperser Clairemix Dissolver (manufactured by M-Technique) to obtain a solution of PLGA and a physiologically active substance. Then, filtration was performed with a 0.2 ⁇ m air vent filter ( ⁇ 62, manufactured by Merck & Co., Ltd.).
- Example 3 The same procedure as in Example 3 was carried out to obtain a microsphere suspension.
- the average volume reference particle diameter of the obtained microspheres was 28.8 ⁇ m, and typical particles were frozen in liquid nitrogen, a FIB cross section was prepared, and an SEM image was observed.
- the PVA aqueous solution was prepared in the same manner as in Reference Example 1. An aqueous PVA solution was placed in advance in a tank for collecting emulsified particles of PLGA and a physiologically active substance, and the mixture was stirred to the extent that the liquid level moved.
- the prepared solution of PLGA and the physiologically active substance and the aqueous solution of PVA were mixed in the same manner as in Reference Example 1 using the particle processing apparatus described in JP-A-2011-189348. Specifically, the prepared PVA aqueous solution was introduced between the first introduction section d1 and the treatment surfaces 1 and 2 at 0.025 MPaG, 50 mL / min, 30 ° C., and the treatment section 10 was rotated at 1800 rpm.
- the prepared solution of PLGA and the physiologically active substance was introduced from the second introduction part d2 between the treatment surfaces 1 and 2 at 0.6 MPaG, 16 mL / min, 30 ° C., and the PVA aqueous solution and the PLGA and the physiologically active substance were introduced.
- a fluid containing the emulsified particles of PLGA and the physiologically active substance (hereinafter referred to as the emulsified particle dispersion of PLGA and the physiologically active substance) between the treatment surfaces 1 and 2 was discharged from the processing surfaces 1 and 2 of the particle processing apparatus.
- the PLGA and the emulsified particle dispersion of the physiologically active substance were collected in a recovery tank via the outer casing 61 for collecting the discharged PLGA and the emulsified particle dispersion of the physiologically active substance.
- the discharged liquid was stirred with a Clairemix dissolver (manufactured by M-Technique) at a peripheral speed of 4.7 m / sec, and argon gas was blown onto the liquid surface for 2.0 hours.
- Dichloromethane was removed by sprinkling to obtain a suspension containing microspheres (microsphere suspension).
- the average volume reference particle diameter of the obtained microspheres was 28.9 ⁇ m, and typical particles were frozen in liquid nitrogen, a FIB cross section was prepared, and an SEM image (FIG. 5) was observed.
- a mass of a physiologically active substance of 1.5 ⁇ m or more was confirmed in the above FIB cross section. It was confirmed that the physiologically active substance was non-uniformly dispersed in the microspheres as fine particles of 0.1 ⁇ m to 1.6 ⁇ m.
- Example 3 As a particle forming step, PLGA and an emulsified particle dispersion of a physiologically active substance were recovered in a recovery tank in the same manner as in Example 4. Next, as a solvent removal step, dichloromethane was removed in the air over 36 hours while stirring the recovered discharge liquid at a peripheral speed of 4.7 m / sec using a Clairemix dissolver (manufactured by M-Technique), and micron. A suspension containing spheres (microsphere suspension) was obtained. The average volume reference particle diameter of the obtained microspheres was 28.6 ⁇ m, and typical particles were frozen in liquid nitrogen, a FIB cross section was prepared, and an SEM image (FIG. 6) was observed.
- a solvent removal step dichloromethane was removed in the air over 36 hours while stirring the recovered discharge liquid at a peripheral speed of 4.7 m / sec using a Clairemix dissolver (manufactured by M-Technique), and micron. A suspension containing spheres (microsphere suspension) was obtained
- a mass of a physiologically active substance of 1.5 ⁇ m or more was confirmed in the above FIB cross section.
- the bioactive substance is non-uniformly dispersed in the microsphere as fine particles of 2.0 ⁇ m to 4.3 ⁇ m, and a large amount of the bioactive substance is particularly present in the surface layer portion (the outermost shell portion of the microsphere). It was confirmed that.
- Tables 1 and 2 show some of the preparation conditions for the microspheres of Examples 1 to 4 and Comparative Examples 1 to 3, the particle size of the prepared microspheres, and the like.
- Example 1 Example 2 and Comparative Example 1
- the particle size of the fine particles of the physiologically active substance changed according to the drying conditions and the drying time. That is, the particle size of the fine particles of the physiologically active substance was 0.1 to 0.22 ⁇ m in Example 1 which was dried in 3.5 hours under the condition of spraying argon, but in 8 hours under the condition of the flow of argon. In the dried Example 2, the size was as large as 0.1 to 0.55 ⁇ m. In Comparative Example 1 which was dried in 15 hours under atmospheric conditions, it was as large as 0.1 to 1.7 ⁇ m, and some exceeded 1.5 ⁇ m.
- the drying conditions and the drying time it is possible to produce the microspheres of the present invention in which there are no lumps or pores of the physiologically active substance of 1.5 ⁇ m or more in the microspheres.
- Example 4 and Comparative Example 2 the particle size of the fine particles of the physiologically active substance changed according to the content of the physiologically active substance. That is, the particle size of the fine particles of the physiologically active substance was 0.3 to 0.7 ⁇ m in Example 3 having a content of 0.75% by mass, but in Example 4 having a content of 1.0% by mass. In Comparative Example 2 in which the content was as large as 0.3 to 0.9 ⁇ m and the content was 2.0% by mass, it was as large as 0.1 to 1.6 ⁇ m and exceeded 1.5 ⁇ m. Further, in Comparative Example 3 which was dried in 36 hours under the condition of the air, it was as large as 2.0 to 4.3 ⁇ m, and some of it exceeded 1.5 ⁇ m. By controlling the content of the physiologically active substance in this way, it is possible to produce the microsphere of the present invention in which there are no lumps or vacancies of the physiologically active substance of 1.5 ⁇ m or more in the microsphere.
- the present invention provides a microsphere in which the initial release amount of a physiologically active substance and the release rate during the subsequent release period are appropriately controlled, and the physiologically active substance can be continuously released in a living body for a certain period of time. be able to.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Abstract
Description
[3]本発明の第3の態様は、分散された前記生理活性物質の平均体積基準粒子径が5nm~500nmである、[1]又は[2]に記載のマイクロスフェアーである。
[4]本発明の第4の態様は、前記生理活性物質が親油性生理活性物質である、[1]~[3]のいずれかに記載のマイクロスフェアーである。
[5]本発明の第5の態様は、[1]~[4]のいずれかに記載のマイクロスフェアーを含有する徐放性製剤である。
本発明のマイクロスフェアーは、生理活性物質が均一に分散された乳酸・グリコール酸共重合体(PLGA)を主成分とするマイクロスフェアーであって、前記マイクロスフェアーの平均体積基準粒子径が1μm以上150μm以下であり、前記マイクロスフェアー中に1.5μm以上の前記生理活性物質の塊又は空孔がないことを特徴とするマイクロスフェアーである。本発明のマイクロスフェアーによって、生理活性物質の初期放出量とその後の放出期間中の放出速度が適切に制御され、生理活性物質を生体内で一定期間、継続して放出することができる。また、前記マイクロスフェアー中に1.5μm以上の前記生理活性物質の塊又は空孔がないにおいて、塊とは生理活性物質の粗大な粒子や凝集体を意味し、空孔とは気泡や溝などの空洞を意味し、1.5μm以上とは、その大きさが略円形の場合最大直径、矩形の場合は長辺、針状の場合も最大長が1.5μm以上を意味する。
マイクロスフェアー中に1.5μm以上又は1.0μm以上の生理活性物質の塊又は空孔がないことは、例えば、分散された生理活性物質の微粒子を確認できる倍率で、マイクロスフェアーの断面を電子顕微鏡写真で観察することで確認することができる。具体的には、先ずマイクロスフェアーを液体窒素により凍結させる。凍結後、FIB(集束イオンビーム:Focused Ion Beam)断面を作成する。すなわち、FIB装置を用いて、集束したイオンビームを試料に照射し、試料内部の所望位置の構造を切り出すことで、マイクロスフェアーの断面を観察する。分散された生理活性物質の微粒子の好ましい粒子径は数10nm~数100nmであるが、この大きさの分散微粒子を確認できる電子顕微鏡の観察倍率でマイクロスフェアーの断面全体を観察する。通常、電子顕微鏡の観察倍率は2500倍から数万倍程度以上である。また、マイクロスフェアー全体を観察できない高い倍率を用いた場合、観察された部分を繋ぎ合わして全体を観察してもよい。生理活性物質の構成元素にもよるが、マイクロスフェアーの断面をEDS(エネルギー分散型X線分光器)で元素分析を行うことができる。
PLGAは、乳酸に由来する構成単位と、グリコール酸に由来する構成単位とを有する乳酸・グリコール酸共重合体である。PLGAは、ポリラクチド(Polylactide,PLA)、ポリグリコリド(Polyglycolide、PGA)等の他の生体分解性高分子を含んでいてもよい。本明細書に記載したPLGAは一例として記載したものであり、記載されたものに制限されるものではない。
本発明のマイクロスフェアーには、PLGA及び生理活性物質が含まれる。更に必要に応じて、分散剤、その他の成分を含有する。マイクロスフェアーのマトリックス中に、生理活性物質、分散剤、その他の成分等が分散されている。
本発明のマイクロスフェアーに含まれる生理活性物質としては、特に制限はなく、目的に応じて適宜選択することができ、例えば、医薬化合物、機能性食品化合物、機能性化粧品化合物等が挙げられる。医薬化合物を含むマイクロスフェアーは、例えば、徐放性医薬製剤として好適に用いることができる。生理活性物質には、親油性生理活性物質及び親水性生理活性物質のいずれもが含まれる。好ましい生理活性物質として親油性生理活性物質が挙げられる。親油性生理活性物質は、例えば、水/オクタノール分配係数のlogP値が3以上である物質を意味し、親油性生理活性物質に含まれない生理活性物質は、親水性生理活性物質に分類される。水/オクタノール分配係数は、JISZ7260-107(2000)フラスコ振とう法に準拠して測定することができる。生理活性物質は、徐放性製剤が望まれるものであれば、特に制限はなく、目的に応じて適宜選択することができる。生理活性物質には、塩、水和物等のいずれの形態も包含される。
分散された生理活性物質の微粒子の平均体積基準粒子径は、5nm~500nmが好ましく、より好ましくは10nm~400nmが挙げられ、更に好ましくは20nm~200nmが挙げられる。
生理活性物質を分散させるために、分散剤を用いることができる。分散剤としては、低分子量の分散剤であってもよく、高分子量の分散剤ポリマーであってもよい。低分子量の分散剤とは、重量平均分子量が15,000未満の化合物を意味し、高分子量の分散剤ポリマーとは、1つ以上のモノマーの間に繰り返しの共有結合を含み、重量平均分子量が15,000以上の化合物を意味する。
本発明のマイクロスフェアーの平均体積基準粒子径は、1μm以上150μm以下であり、10μm以上100μm以下が好ましく、20μm以上75μm以下がより好ましい。平均体積基準粒子径は、レーザー回折式粒度分布測定装置を用いて測定することができる。本発明においては、平均体積基準粒子径が、150μmを超えると、マイクロスフェアー内の生理活性物質の分散不均一性によって初期バーストの問題が発生し、凝集や沈降し易くなり、後工程の処理も難しくなる。1μmより小さくなると著しく初期バーストの問題が発生する。
本発明のマイクロスフェアーを用いて、マイクロスフェアーを含有する徐放性製剤を調製することができる。本発明の徐放性製剤によって、生理活性物質の初期放出量とその後の放出期間中の放出速度が適切に制御され、生理活性物質を生体内で一定期間、継続して放出し、有効に薬理学的効果を示すことができる。
<マイクロスフェアーの製造工程>
本発明のマイクロスフェアーの製造方法は、粒子形成工程を少なくとも含み、更に必要に応じて、ろ過滅菌工程、良溶媒除去工程、その他の工程等を含んでもよい。
粒子形成工程は、特開2009-132871号公報又は特開2011-189348号公報に記載の接近離反可能な対向して配設された、少なくとも一方が他方に対して相対的に回転する複数の処理用面の間で粒子化処理がなされる粒子化処理装置を用いることが好ましい。粒子形成工程は、例えば、前記の粒子化処理装置を用いて、PLGAの良溶媒にPLGA及び生理活性物質を溶解又は分散させて得られるPLGA及び生理活性物質の溶液と、PLGAの貧溶媒を含む溶液とを連続投入して、乳化粒子を作製し、作製された粒子から良溶媒を除去することによって、本発明のマイクロスフェアーを析出させることで実施される。ここで、「分散」とは、生理活性物質を固体のままPLGAの良溶媒に分散させること、生理活性物質をPLGAの良溶媒に乳化させること、親水性生理活性物質の水性溶液とPLGAの良溶媒を含むw/oエマルションを形成させること等を含む。
必要に応じて、粒子形成工程の前に、調製されたPLGA及び生理活性物質の溶液並びに貧溶媒を含む溶液の無菌ろ過を行うことも好ましい。貧溶媒を含む溶液は親水性フィルターを用いて、PLGA及び生理活性物質の溶液は疎水性フィルターを用いてろ過滅菌することができる。ろ過に用いるフィルターの孔径は0.1μm~0.45μmが好ましく、0.2μmがより好ましい。
良溶媒除去工程において、PLGA及び生理活性物質を含む前記乳化粒子から良溶媒を除去する。良溶媒除去工程は、マイクロスフェアーの断面に1.5μm以上の生理活性物質の塊又は空孔が生じないようにして、前記乳化粒子を含有する液から前記良溶媒を除去することができれば、特に制限はなく、目的に応じて適宜選択することができる。例えば、撹拌しながら前記液を加熱すること、前記液の液面に窒素などのガスをフローすること、及び前記液を減圧させることの少なくともいずれかにより、前記良溶媒を蒸発させて前記液から除去する方法などが挙げられる。マイクロスフェアー中に1.5μm以上又は1.0μm以上の生理活性物質の塊又は空孔が生じないようにするためには、良溶媒を早く除去することが好ましい。良溶媒を除去する時間としては、例えば、30分間~12時間が挙げられ、好ましくは1~10時間が挙げられ、より好ましくは2~8時間が挙げられる。
その他の工程としては、例えば、溶媒組成調製、分級工程、粒子洗浄工程などが挙げられる。通常、分級工程において粗粉カットや微粉カットが行われるが、本発明において製造した粒子は、実質的に分級工程を行う必要はなくなる。但し、念のため分級工程を含んでおいても構わない。
参考例1で、生理活性物質を含まないマイクロスフェアー(PLGA微粒子)を作製した。参考例1のマイクロスフェアーを指標に用いて、実施例及び比較例のマイクロスフェアーの断面をSEM画像で観察することで、実施例及び比較例のマイクロスフェアー中の生理活性物質の分散状態を、以下で確認した。
乳酸・グリコール酸共重合体(Resomer RG504,エボニック製)が13質量%なるようにジクロロメタン(関東化学製)を加え、高速回転式分散機クレアミックスディゾルバー(エム・テクニック製)を用いて溶解させ、PLGA溶液を得た。その後、0.2μmのベントフィルター(φ62,メルク製)でろ過を行った。ポリビニルアルコール(PVA,EG-40P,日本合成化学工業製)が1.5質量%となるようにイオン交換水を加え、高速回転式分散機クレアミックス(エム・テクニック製)を用いて溶解させ、PVA水溶液を得た。その後、親水性PVDFメンブレンフィルター(φ47,メルク製)でろ過を行った。PLGA乳化粒子を回収するタンクに予めPVA水溶液を入れ、液面が動く程度に撹拌を行った。
粒子形成工程として、調製したPLGA溶液とPVA水溶液とを特開2011-189348号公報に記載の粒子化処理装置を用いて混合した。ここで特開2011-189348号公報に記載の粒子化処理装置とは、同公報の図25に記載の装置であって、第2導入口d20がリング状ディスクである処理用面2の中央の開口を取り巻く同心円状の円環形状であるものであり、ディスク直径は75mmである。具体的には、調製されたPVA水溶液を第1導入部d1から処理用面1、2間に、0.02MPaG、65mL/分、30℃で導入し、処理用部10を2000rpmで回転させながら、調製されたPLGA溶液を第2導入部d2から処理用面1、2間に、0.65MPaG、20mL/分、30℃で導入して、PVA水溶液とPLGA溶液とを強制薄膜中で混合し、処理用面1、2間においてジクロロメタンを含むPLGA乳化粒子を作製した。処理用面1、2間におけるPLGA乳化粒子を含む流体(以下、PLGA乳化粒子分散液)を粒子化処理装置の処理用面1、2間から吐出させた。吐出させたPLGA乳化粒子分散液を捕集するためのアウターケーシング61を介してPLGA乳化粒子分散液を、回収タンクに回収した。
<PLGA及び生理活性物質の溶液とPVA水溶液の調製>
乳酸・グリコール酸共重合体(Resomer RG504,エボニック製)が13質量%に、生理活性物質としてプロゲステロン(富士フイルム和光純薬製,細胞生化学用)が1.0質量%になるようにジクロロメタン(関東化学製)を加え、高速回転式分散機クレアミックスディゾルバー(エム・テクニック製)を用いて溶解させ、PLGA及び生理活性物質の溶液を得た。その後、0.2μmのエアベントフィルター(φ62,メルク製)でろ過を行った。PVA水溶液は、参考例1と同様にして調製した。PLGA及び生理活性物質の乳化粒子を回収するタンクに予めPVA水溶液を入れ、液面が動く程度に撹拌を行った。
粒子形成工程として、参考例1と同様にして、調製されたPLGA及び生理活性物質の溶液とPVA水溶液とを、特開2011-189348号公報に記載の粒子化処理装置を用いて混合した。具体的には、調製されたPVA水溶液を第1導入部d1から処理用面1、2間に、0.02MPaG、65mL/分、30℃で導入し、処理用部10を2000rpmで回転させながら、調製されたPLGA及び生理活性物質の溶液を第2導入部d2から処理用面1、2間に、0.65MPaG、20mL/分、30℃で導入して、PVA水溶液とPLGA及び生理活性物質の溶液とを強制薄膜中で混合し、処理用面1、2間においてジクロロメタンを含むPLGA及び生理活性物質の乳化粒子を作製した。処理用面1、2間におけるPLGA及び生理活性物質の乳化粒子を含む流体(以下、PLGA及び生理活性物質の乳化粒子分散液)を粒子化処理装置の処理用面1、2間から吐出させた。吐出させたPLGA及び生理活性物質の乳化粒子分散液を捕集するためのアウターケーシング61を介して、PLGA及び生理活性物質の乳化粒子分散液を、回収タンクに回収した。
実施例1と同様にして、粒子形成工程として、PLGA及び生理活性物質の乳化粒子分散液を調製した。次に脱溶媒工程として、回収した吐出液をクレアミックスディゾルバー(エム・テクニック製)を用いて、周速度4.7m/秒で撹拌しながら、アルゴンガスをフローして8時間かけてジクロロメタンを除去し、マイクロスフェアーを含む懸濁液(マイクロスフェアー懸濁液)を得た。得られたマイクロスフェアーの平均体積基準粒子径は35.3μmであり、代表的な粒子を液体窒素により凍結後、FIB断面を作成し、SEM画像を観察した。
実施例1と同様にして、粒子形成工程として、PLGA及び生理活性物質の乳化粒子分散液を調製した。次に脱溶媒工程として、回収した吐出液をクレアミックスディゾルバー(エム・テクニック製)を用いて、周速度4.7m/秒で撹拌しながら、大気中で15時間かけてジクロロメタンを除去し、マイクロスフェアーを含む懸濁液(マイクロスフェアー懸濁液)を得た。得られたマイクロスフェアーの平均体積基準粒子径は35.4μmであり、代表的な粒子を液体窒素により凍結後、FIB断面を作成し、SEM画像を観察した。
乳酸・グリコール酸共重合体(Resomer RG504,エボニック製)が13質量%に、生理活性物質としてプロブコール(富士フイルム和光純薬製、生化学用)が0.75質量%になるようにジクロロメタン(関東化学製)を加え、高速回転式分散機クレアミックスディゾルバー(エム・テクニック製)を用いて溶解させ、PLGA及び生理活性物質の溶液を得た。その後、0.2μmのエアベントフィルター(φ62,メルク製)でろ過を行った。PVA水溶液は、参考例1と同様にして調製した。PLGA及び生理活性物質の乳化粒子を回収するタンクに予めPVA水溶液を入れ、液面が動く程度に撹拌を行った。
粒子形成工程として、参考例1と同様にして、調製されたPLGA及び生理活性物質の溶液とPVA水溶液とを特開2011-189348号公報に記載の粒子化処理装置を用いて混合した。具体的には、調製されたPVA水溶液を第1導入部d1から処理用面1、2間に、0.025MPaG、50mL/分、30℃で導入し、処理用部10を1800rpmで回転させながら、調製されたPLGA及び生理活性物質の溶液を第2導入部d2から処理用面1、2間に、0.6MPaG、16mL/分、30℃で導入して、PVA水溶液とPLGA及び生理活性物質の溶液とを強制薄膜中で混合し、処理用面1、2間においてジクロロメタンを含むPLGA及び生理活性物質の乳化粒子を作製した。処理用面1、2間におけるPLGA及び生理活性物質の乳化粒子を含む流体(以下、PLGA及び生理活性物質の乳化粒子分散液)を粒子化処理装置の処理用面1、2間から吐出させた。吐出させたPLGA及び生理活性物質乳化粒子分散液を捕集するためのアウターケーシング61を介して、PLGA及び生理活性物質の乳化粒子分散液を、回収タンクに回収した。
乳酸・グリコール酸共重合体(Resomer RG504,エボニック製)が13質量%に、生理活性物質としてプロブコール(富士フイルム和光純薬製,生化学用)が1.0質量%になるようにジクロロメタン(関東化学製)を加え、高速回転式分散機クレアミックスディゾルバー(エム・テクニック製)を用いて溶解させ、PLGA及び生理活性物質の溶液を得た。その後、0.2μmのエアベントフィルター(φ62,メルク製)でろ過を行った。その後、実施例3と同様に実施して、マイクロスフェアー懸濁液を得た。得られたマイクロスフェアーの平均体積基準粒子径は28.8μmであり、代表的な粒子を液体窒素により凍結後、FIB断面を作成し、SEM画像を観察した。
乳酸・グリコール酸共重合体(Resomer RG504,エボニック製)が13質量%に、生理活性物質としてプロブコール(富士フイルム和光純薬製、生化学用)が2.0質量%になるようにジクロロメタン(関東化学製)を加え、高速回転式分散機クレアミックスディゾルバー(エム・テクニック製)を用いて溶解させ、PLGA及び生理活性物質の溶液を得た。その後、0.2μmのエアベントフィルター(φ62,メルク製)でろ過を行った。PVA水溶液は、参考例1と同様にして調製した。PLGA及び生理活性物質の乳化粒子を回収するタンクに予めPVA水溶液を入れ、液面が動く程度に撹拌を行った。
粒子形成工程として、参考例1と同様にして、調製されたPLGA及び生理活性物質の溶液とPVA水溶液とを特開2011-189348号公報に記載の粒子化処理装置を用いて混合した。具体的には、調製されたPVA水溶液を第1導入部d1から処理用面1、2間に、0.025MPaG、50mL/分、30℃で導入し、処理用部10を1800rpmで回転させながら、調製されたPLGA及び生理活性物質の溶液を第2導入部d2から処理用面1、2間に、0.6MPaG、16mL/分、30℃で導入して、PVA水溶液とPLGA及び生理活性物質の溶液とを強制薄膜中で混合し、処理用面1、2間においてジクロロメタンを含むPLGA及び生理活性物質の乳化粒子を作製した。処理用面1、2間におけるPLGA及び生理活性物質の乳化粒子を含む流体(以下、PLGA及び生理活性物質の乳化粒子分散液)を粒子化処理装置の処理用面1、2間から吐出させた。吐出させたPLGA及び生理活性物質の乳化粒子分散液を捕集するためのアウターケーシング61を介して、PLGA及び生理活性物質の乳化粒子分散液を、回収タンクに回収した。
粒子形成工程として、実施例4と同様にして、PLGA及び生理活性物質の乳化粒子分散液を、回収タンクに回収した。次に脱溶媒工程として、回収された吐出液をクレアミックスディゾルバー(エム・テクニック製)を用いて周速度4.7m/秒で撹拌しながら、大気中で36時間かけてジクロロメタンを除去し、マイクロスフェアーを含む懸濁液(マイクロスフェアー懸濁液)を得た。得られたマイクロスフェアーの平均体積基準粒子径は28.6μmであり、代表的な粒子を液体窒素により凍結後、FIB断面を作成し、SEM画像(図6)を観察した。
Claims (5)
- 生理活性物質が均一に分散された乳酸・グリコール酸共重合体(PLGA)を主成分とするマイクロスフェアーであって、
前記マイクロスフェアーの平均体積基準粒子径が1μm以上150μm以下であり、
前記マイクロスフェアー中に1.5μm以上の前記生理活性物質の塊又は空孔がないことを特徴とするマイクロスフェアー。 - 前記マイクロスフェアー中に1.0μm以上の前記生理活性物質の塊又は空孔がない、請求項1に記載のマイクロスフェアー。
- 分散された前記生理活性物質の平均体積基準粒子径が5nm~500nmである、請求項1又は2に記載のマイクロスフェアー。
- 前記生理活性物質が親油性生理活性物質である、請求項1~3のいずれかに記載のマイクロスフェアー。
- 請求項1~4のいずれかに記載のマイクロスフェアーを含有する徐放性製剤。
Priority Applications (23)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2020/018731 WO2021224999A1 (ja) | 2020-05-08 | 2020-05-08 | 生理活性物質が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤 |
KR1020227038098A KR20220163418A (ko) | 2020-05-08 | 2020-05-08 | 생리 활성 물질이 균일하게 분산된 마이크로스피어 및 그것을 함유하는 서방성 제제 |
EP20934379.7A EP4147720A4 (en) | 2020-05-08 | 2020-05-08 | MICROPHONES WITH A UNIFORMLY DISPERSED BIOACTIVE SUBSTANCE AND PREPARATION WITH DELAYED RELEASE CONTAINING THEM |
CN202080100594.7A CN115551550A (zh) | 2020-05-08 | 2020-05-08 | 均匀分散有生理活性物质的微球及含有其的缓释制剂 |
US17/259,371 US20210346296A1 (en) | 2020-05-08 | 2020-05-08 | A biologically active substance uniformly dispersed microsphere and a sustained release formulation comprising the same |
JP2020539298A JP6792900B1 (ja) | 2020-05-08 | 2020-05-08 | 生理活性物質が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤 |
EP20934454.8A EP4147721A4 (en) | 2020-05-08 | 2020-09-11 | MICRO SPHERE HAVING A PHYSIOLOGICALLY ACTIVE SUBSTANCE EVENLY DISPERSED THEREIN AND DELAYED RELEASE PREPARATION CONTAINING SAME |
US17/259,690 US11285109B2 (en) | 2020-05-08 | 2020-09-11 | Microsphere comprising PLGA or PLA in which a biologically active substance is uniformly dispersed and a sustained release formulation comprising the same |
KR1020227038094A KR20220163416A (ko) | 2020-05-08 | 2020-09-11 | 생리 활성 물질이 균일하게 분산된 마이크로스피어 및 그것을 함유하는 서방성 제제 |
CN202080100595.1A CN115551485A (zh) | 2020-05-08 | 2020-09-11 | 均匀分散有生理活性物质的微球及含有其的缓释制剂 |
JP2020562225A JP6810502B1 (ja) | 2020-05-08 | 2020-09-11 | 生理活性物質が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤 |
PCT/JP2020/034524 WO2021225011A1 (ja) | 2020-05-08 | 2020-09-11 | 生理活性物質が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤 |
PCT/JP2020/044366 WO2021225013A1 (ja) | 2020-05-08 | 2020-11-27 | 主剤が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤 |
JP2021504315A JP6852943B1 (ja) | 2020-05-08 | 2020-11-27 | 主剤が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤 |
CN202080025520.1A CN114174385B (zh) | 2020-05-08 | 2020-11-27 | 主剂均匀分散的微球和含有其的缓释制剂 |
US17/269,002 US11617720B2 (en) | 2020-05-08 | 2020-11-27 | Main agent uniformly dispersed microsphere and a sustained release formulation comprising the same |
KR1020227038097A KR20220163417A (ko) | 2020-05-08 | 2020-11-27 | 주제가 균일하게 분산된 마이크로스피어 및 그것을 함유하는 서방성 제제 |
CN202310232792.4A CN116327735A (zh) | 2020-05-08 | 2020-11-27 | 主剂均匀分散的微球和含有其的缓释制剂 |
EP20934643.6A EP4147722A4 (en) | 2020-05-08 | 2020-11-27 | MICROSPHERES CONTAINING UNIFORMLY DISPERSED PRIMARY AGENT AND SUSTAINED RELEASE PREPARATION COMPRISING MICROSPHERES CONTAINING UNIFORMLY DISPERSED PRIMARY AGENT |
JP2021034353A JP2021176833A (ja) | 2020-05-08 | 2021-03-04 | 主剤が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤 |
US17/673,429 US20220168224A1 (en) | 2020-05-08 | 2022-02-16 | Microsphere comprising plga or pla in which a biologically active substance is uniformly dispersed and a sustained release formulation comprising the same |
US18/112,747 US20230190658A1 (en) | 2020-05-08 | 2023-02-22 | Main agent uniformly dispersed microsphere and a sustained release formulation comprising the same |
US18/349,753 US20230346706A1 (en) | 2020-05-08 | 2023-07-10 | Biologically active substance uniformly dispersed microsphere and a sustained release formulation comprising the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2020/018731 WO2021224999A1 (ja) | 2020-05-08 | 2020-05-08 | 生理活性物質が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/259,371 A-371-Of-International US20210346296A1 (en) | 2020-05-08 | 2020-05-08 | A biologically active substance uniformly dispersed microsphere and a sustained release formulation comprising the same |
US18/349,753 Continuation US20230346706A1 (en) | 2020-05-08 | 2023-07-10 | Biologically active substance uniformly dispersed microsphere and a sustained release formulation comprising the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021224999A1 true WO2021224999A1 (ja) | 2021-11-11 |
Family
ID=73544650
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2020/018731 WO2021224999A1 (ja) | 2020-05-08 | 2020-05-08 | 生理活性物質が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤 |
PCT/JP2020/034524 WO2021225011A1 (ja) | 2020-05-08 | 2020-09-11 | 生理活性物質が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤 |
PCT/JP2020/044366 WO2021225013A1 (ja) | 2020-05-08 | 2020-11-27 | 主剤が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2020/034524 WO2021225011A1 (ja) | 2020-05-08 | 2020-09-11 | 生理活性物質が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤 |
PCT/JP2020/044366 WO2021225013A1 (ja) | 2020-05-08 | 2020-11-27 | 主剤が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20210346296A1 (ja) |
EP (3) | EP4147720A4 (ja) |
JP (1) | JP6792900B1 (ja) |
KR (1) | KR20220163418A (ja) |
CN (1) | CN115551550A (ja) |
WO (3) | WO2021224999A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230165798A1 (en) * | 2018-10-12 | 2023-06-01 | Hovione Scientia | Macrocyclic lactone formulations, methods of their preparation and use of the formulations in treating pathologies secondary to ophthalmic parasites |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04114725A (ja) | 1990-09-01 | 1992-04-15 | M Technic Kk | 撹拌機及び流体の撹拌方法 |
JP2653255B2 (ja) | 1990-02-13 | 1997-09-17 | 武田薬品工業株式会社 | 長期徐放型マイクロカプセル |
JP2001512461A (ja) * | 1997-02-13 | 2001-08-21 | オークウッド ラボラトリーズ エル.エル.シィ. | 連続ミクロスフェア製法 |
JP2002534392A (ja) * | 1998-12-30 | 2002-10-15 | ドン クック ファーマシューティカル カンパニー リミテッド | 黄体化ホルモン放出ホルモン類似体をカプセル化する持続放出性のマイクロスフェアおよびその調製方法 |
JP2005015476A (ja) | 2003-06-03 | 2005-01-20 | Santen Pharmaceut Co Ltd | 微粒子の製造法 |
JP2005035994A (ja) | 2003-06-26 | 2005-02-10 | Peptron Co Ltd | 徐放性マイクロスフェアの混合剤型を連続単一工程で製造する方法 |
JP2009520727A (ja) * | 2005-12-22 | 2009-05-28 | ノバルティス アクチエンゲゼルシャフト | オクトレオチドおよび2種またはそれ以上のポリラクチドコグリコリドポリマーを含む徐放性製剤 |
JP2009132871A (ja) | 2007-11-09 | 2009-06-18 | M Technique Co Ltd | 樹脂微粒子水分散体の製造方法及びこの製造方法にて得られた樹脂微粒子水分散体、樹脂微粒子 |
JP2010510206A (ja) * | 2006-11-27 | 2010-04-02 | ドンコック ファーマシューティカル コー. エルティーディー. | 優れた初期放出抑制特性を有する徐放性マイクロカプセルの製造方法及びこれにより製造されるマイクロカプセル |
JP2010531303A (ja) | 2007-06-25 | 2010-09-24 | 大塚製薬株式会社 | コア/シェル構造を有するマイクロスフェア |
JP2011189348A (ja) | 2007-07-06 | 2011-09-29 | M Technique Co Ltd | 強制超薄膜回転式処理法を用いた微粒子の製造方法 |
JP4856752B2 (ja) | 2009-11-30 | 2012-01-18 | ホソカワミクロン株式会社 | 薬物含有ナノ粒子の製造方法 |
JP5147091B1 (ja) | 2012-07-13 | 2013-02-20 | エム・テクニック株式会社 | 攪拌機 |
JP2014224114A (ja) | 2013-05-15 | 2014-12-04 | シージェイ チェイルジェダン コーポレーションCj Cheiljedang Corporation | 連続工程のマイクロスフェアの製造方法及びそれにより製造されたマイクロスフェア |
JP2016069378A (ja) | 2014-09-26 | 2016-05-09 | コヴィディエン リミテッド パートナーシップ | 手術後の慢性の痛みのための薬物充填マイクロスフェア |
JP2017509661A (ja) * | 2014-03-31 | 2017-04-06 | ファーマシェン エス.エー. | 徐放特性を持つペプチド充填plgaミクロスフェアの調製 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6510400A (en) * | 1999-08-04 | 2001-03-05 | Oakwood Laboratories L.L.C. | Slow release microspheres |
US20080102131A1 (en) | 2006-10-31 | 2008-05-01 | Kaneka Corporation | Particulate composition comprising bioactive substance and method of producing the same |
US8114561B2 (en) * | 2007-07-06 | 2012-02-14 | Sharp Kabushiki Kaisha | Toner, method of manufacturing the toner, developing device, and image forming apparatus |
BR112018009644A2 (pt) * | 2015-11-12 | 2018-11-06 | Graybug Vision Inc | micropartículas agregantes sólidas modificadas na superfície, material injetável, processo para preparação de micropartículas agregantes sólidas modificadas na superfície, método para tratamento de um distúrbio ocular, e, uso de micropartículas agregantes sólidas modificadas na superfície |
US11285109B2 (en) * | 2020-05-08 | 2022-03-29 | M. Technique Co., Ltd. | Microsphere comprising PLGA or PLA in which a biologically active substance is uniformly dispersed and a sustained release formulation comprising the same |
-
2020
- 2020-05-08 JP JP2020539298A patent/JP6792900B1/ja active Active
- 2020-05-08 KR KR1020227038098A patent/KR20220163418A/ko unknown
- 2020-05-08 WO PCT/JP2020/018731 patent/WO2021224999A1/ja unknown
- 2020-05-08 EP EP20934379.7A patent/EP4147720A4/en active Pending
- 2020-05-08 US US17/259,371 patent/US20210346296A1/en not_active Abandoned
- 2020-05-08 CN CN202080100594.7A patent/CN115551550A/zh active Pending
- 2020-09-11 EP EP20934454.8A patent/EP4147721A4/en active Pending
- 2020-09-11 WO PCT/JP2020/034524 patent/WO2021225011A1/ja unknown
- 2020-11-27 WO PCT/JP2020/044366 patent/WO2021225013A1/ja unknown
- 2020-11-27 EP EP20934643.6A patent/EP4147722A4/en active Pending
-
2023
- 2023-07-10 US US18/349,753 patent/US20230346706A1/en active Pending
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2653255B2 (ja) | 1990-02-13 | 1997-09-17 | 武田薬品工業株式会社 | 長期徐放型マイクロカプセル |
JPH04114725A (ja) | 1990-09-01 | 1992-04-15 | M Technic Kk | 撹拌機及び流体の撹拌方法 |
JP2001512461A (ja) * | 1997-02-13 | 2001-08-21 | オークウッド ラボラトリーズ エル.エル.シィ. | 連続ミクロスフェア製法 |
JP2002534392A (ja) * | 1998-12-30 | 2002-10-15 | ドン クック ファーマシューティカル カンパニー リミテッド | 黄体化ホルモン放出ホルモン類似体をカプセル化する持続放出性のマイクロスフェアおよびその調製方法 |
JP2005015476A (ja) | 2003-06-03 | 2005-01-20 | Santen Pharmaceut Co Ltd | 微粒子の製造法 |
JP2005035994A (ja) | 2003-06-26 | 2005-02-10 | Peptron Co Ltd | 徐放性マイクロスフェアの混合剤型を連続単一工程で製造する方法 |
JP2009520727A (ja) * | 2005-12-22 | 2009-05-28 | ノバルティス アクチエンゲゼルシャフト | オクトレオチドおよび2種またはそれ以上のポリラクチドコグリコリドポリマーを含む徐放性製剤 |
JP2010510206A (ja) * | 2006-11-27 | 2010-04-02 | ドンコック ファーマシューティカル コー. エルティーディー. | 優れた初期放出抑制特性を有する徐放性マイクロカプセルの製造方法及びこれにより製造されるマイクロカプセル |
JP2010531303A (ja) | 2007-06-25 | 2010-09-24 | 大塚製薬株式会社 | コア/シェル構造を有するマイクロスフェア |
JP2011189348A (ja) | 2007-07-06 | 2011-09-29 | M Technique Co Ltd | 強制超薄膜回転式処理法を用いた微粒子の製造方法 |
JP2009132871A (ja) | 2007-11-09 | 2009-06-18 | M Technique Co Ltd | 樹脂微粒子水分散体の製造方法及びこの製造方法にて得られた樹脂微粒子水分散体、樹脂微粒子 |
JP4856752B2 (ja) | 2009-11-30 | 2012-01-18 | ホソカワミクロン株式会社 | 薬物含有ナノ粒子の製造方法 |
JP5147091B1 (ja) | 2012-07-13 | 2013-02-20 | エム・テクニック株式会社 | 攪拌機 |
JP2014224114A (ja) | 2013-05-15 | 2014-12-04 | シージェイ チェイルジェダン コーポレーションCj Cheiljedang Corporation | 連続工程のマイクロスフェアの製造方法及びそれにより製造されたマイクロスフェア |
JP2017509661A (ja) * | 2014-03-31 | 2017-04-06 | ファーマシェン エス.エー. | 徐放特性を持つペプチド充填plgaミクロスフェアの調製 |
JP2016069378A (ja) | 2014-09-26 | 2016-05-09 | コヴィディエン リミテッド パートナーシップ | 手術後の慢性の痛みのための薬物充填マイクロスフェア |
Also Published As
Publication number | Publication date |
---|---|
EP4147720A4 (en) | 2023-04-26 |
EP4147721A1 (en) | 2023-03-15 |
JP6792900B1 (ja) | 2020-12-02 |
US20210346296A1 (en) | 2021-11-11 |
EP4147722A4 (en) | 2023-11-29 |
US20230346706A1 (en) | 2023-11-02 |
EP4147721A4 (en) | 2023-11-29 |
JPWO2021224999A1 (ja) | 2021-11-11 |
WO2021225013A1 (ja) | 2021-11-11 |
EP4147720A1 (en) | 2023-03-15 |
EP4147722A1 (en) | 2023-03-15 |
KR20220163418A (ko) | 2022-12-09 |
WO2021225011A1 (ja) | 2021-11-11 |
CN115551550A (zh) | 2022-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6810502B1 (ja) | 生理活性物質が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤 | |
CA2793241C (en) | Method for preparing nano-particles | |
EP1180062B1 (de) | Verfahren zur herstellung von morphologisch einheitlichen mikro- und nanopartikeln mittels eines mikromischers | |
AU2004295259B2 (en) | Method for preparing nano-scale or amorphous particle using solid fat as a solvent | |
US20230346706A1 (en) | Biologically active substance uniformly dispersed microsphere and a sustained release formulation comprising the same | |
JP6852943B1 (ja) | 主剤が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤 | |
JP6788171B1 (ja) | Plga微粒子、その徐放性製剤及びその製造方法 | |
KR101342121B1 (ko) | 저온 및 저압 하에서 초임계유체를 이용한 나노수준의활성물질 입자 제조방법 | |
KR102096864B1 (ko) | 탄화수소를 이용한 나노수준의 활성물질 입자 제조방법 | |
WO2007000842A1 (ja) | 粒状物分散組成物及びその製造方法、並びに、粒状物及び医薬品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2020539298 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20934379 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20227038098 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020934379 Country of ref document: EP Effective date: 20221208 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |